Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.
暂无分享,去创建一个
M. Ladanyi | C. Rudin | M. Kris | M. Arcila | Gregory Riely | M. Hellmann | G. Heller | A. Knezevic | P. Lito | D. Halpenny | H. Rizvi | A. Plodkowski | K. Arbour | H. Yu